On 4/25, we're hosting an educational webinar to dive into mast cell biology, exploring its role in a range of allergic and inflammatory diseases. This event is geared toward educating about emerging opportunities for mast cell-targeted therapies: bit.ly/3VVa7tB

Working with MD Anderson Cancer Center, we aim to uncover the broad potential of CDK2 inhibition in cancer treatment. At #AACR24 , we reported preclinical breast cancer data showing the activity of our investigational CDK2 inhibitor in combination with a CDK4/6 inhibitor.

CDK2 is a key driver of tumor growth in HR+/HER2- metastatic breast cancer. We're committed to exploring new avenues for treating this cancer that may overcome resistance. Learn about our CDK2 inhibitor in development at #AACR24 .

We're sharing posters from our program in CDK2-vulnerable cancers at #AACR24 . HCPs can visit our #BlueCrew to learn about our latest breast cancer and preclinical endometrial cancer data, offering insights into the role of CDK2 inhibition in the treatment of these diseases.

Systemic mastocytosis is a rare, clonal mast cell disease often marked by a KIT D816V mutation. Our PROSPECTOR study looked at the mutation's frequency in peripheral blood in people presenting w/ systemic mast cell activation symptoms, yet no SM diagnosis:bit.ly/43z6oUq

Utilizing high sensitivity testing to detect the KIT D816V mutation can help clinicians diagnose systemic mastocytosis (SM). With enhanced detection rates, a high sensitivity KIT D816V lab assay may help with diagnosing SM.

Indolent systemic mastocytosis (ISM) patients may commonly present with skin symptoms, including skin lesions. We look forward to engaging dermatologists at the Medical Dermatology Society 2024 Annual Meeting to increase awareness of ISM and support diagnostic efforts.

n #RareDiseaseDay , we reflect on our commitment to understand patient needs and build meaningful connections with rare disease communities. We're proud to support this global day dedicated to raising awareness for rare diseases like SM and working to improve patient care.

At #AAAAI24 , our #BlueCrew showcased our commitment to improving patient care for systemic mastocytosis and other mast cell disorders, as we engaged with healthcare professionals and advocates across allergy/immunology. Hear about our team's experience at this year's meeting.

Our CEO Kate Haviland has been recognized on CNBC's inaugural list of 'Changemakers: Women transforming business'. We're honored to be led by a trailblazing woman like Kate, whose leadership drives our mission forward. Read her profile: cnb.cx/4bM5WFU #CNBCChangemakers

People living w/ systemic mastocytosis may face a significant disease burden, including challenges receiving a timely diagnosis. We look forward to connecting w/ healthcare professionals & the advocacy community at #AAAAI24 as we work toward our goal of enhancing SM patient care.

At #AAAAI24 , we're sharing data reflecting our progress toward our goal of transforming care for mast cell disorders, including long-term data from our PIONEER trial in indolent systemic mastocytosis & preclinical data for our wild-type KIT program: bit.ly/49mX73S

We look forward to sharing clinical and real-world data on systemic mastocytosis, and preclinical research from our wild-type KIT program. Catch us at #AAAAI24 at Booth 351 or during our oral and poster presentations showcasing our expertise in mast cell disorders.

Today, we announced our Q4 and full year 2023 results. Join our live investor webcast at 8 a.m. ET or read our press release here: bit.ly/48kozxZ

We're extending our expertise of KIT-driven mast cell disorders into allergic-inflammatory diseases such as chronic urticaria, a burdensome skin disorder characterized by hives or wheals. We're leveraging our scientific knowledge to help improve the lives of more people.

On this #WorldCancerDay , we're supporting efforts to #CloseTheCareGap by advancing the promise of precision medicine. By selectively inhibiting CDK2, a well-recognized cell cycle target, we aim to bring our innovation to those living with breast cancer.

Building on our profound understanding of systemic mastocytosis and the KIT receptor as a clinically validated target, we're expanding our commitment to patients with mast cell disorders to include chronic urticaria. With our scientific platform, we aim to help more patients.

We celebrate dedicated care teams who support people living w/ systemic mastocytosis (SM), as it can be difficult to manage & mitigate reactions related to the disease. If you care for someone w/ SM, it's key to listen to how they describe symptoms & pinpoint potential triggers.

We aim to enhance diagnosis of systemic mastocytosis & the understanding of its impacts on daily living. Our Health Economics & Outcomes Research team uses real-world data to help build a clearer story of what it's like living w/ SM. Read more in our blog: bit.ly/3U3UHT2

Our CEO Kate Haviland is participating in a #FierceJPM panel tomorrow, where she will share how Blueprint Medicines evolved from an R&D stage company to a fully integrated organization, with capabilities from drug discovery to commercialization. #JPM24